Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of li...
Gespeichert in:
Veröffentlicht in: | Alimentary pharmacology & therapeutics 2024-07, Vol.60 (1), p.61-69 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 69 |
---|---|
container_issue | 1 |
container_start_page | 61 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 60 |
creator | Tamaki, Nobuharu Kimura, Takefumi Wakabayashi, Shun‐Ichi Umemura, Takeji Kurosaki, Masayuki Loomba, Rohit Izumi, Namiki |
description | Summary
Background
A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown.
Aims
To evaluate the risk of liver‐related events, MACE and death among patients with SLD.
Methods
We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD.
Results
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p |
doi_str_mv | 10.1111/apt.18015 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3047948769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3066183072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</originalsourceid><addsrcrecordid>eNp1kc-KFDEQh4Mo7rh68AUk4EXB3k0nk3RyXJb1DwzoYT03NUm1ZEl3xiQ9y9x8hPUVfRKz26MHwVwKUl99FPUj5GXLztr6zmFXzlrNWvmIrFqhZMOZUI_JinFlGq5bcUKe5XzDGFMd40_JidBKrXWnVuTnJk7ffv24K5hGaoOfvIVA41xsHDFTP9FcEEos3tLg95io8xkhI4XJ1bb1DieLNA5Lu6oSBijoKO5xKvkdtZCcj3vIdg6Qjt8P4xBC5S3MVTfGVCD4cnhOngwQMr441lPy9f3V9eXHZvP5w6fLi01jhRSycRy4MQqtFGZQSsuOraW1ej3AlivXOdOBE8AtFxq0kVuo1xBGO-NAttaKU_Jm8e5S_D5jLv3os8UQYMI4516wdWfuj2Qq-vof9CbOaarbVUqpVgvW8Uq9XSibYs4Jh36X_Ajp0Lesv8-przn1DzlV9tXROG9HdH_JP8FU4HwBbn3Aw_9N_cWX60X5G6lmobk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3066183072</pqid></control><display><type>article</type><title>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Tamaki, Nobuharu ; Kimura, Takefumi ; Wakabayashi, Shun‐Ichi ; Umemura, Takeji ; Kurosaki, Masayuki ; Loomba, Rohit ; Izumi, Namiki</creator><creatorcontrib>Tamaki, Nobuharu ; Kimura, Takefumi ; Wakabayashi, Shun‐Ichi ; Umemura, Takeji ; Kurosaki, Masayuki ; Loomba, Rohit ; Izumi, Namiki</creatorcontrib><description>Summary
Background
A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown.
Aims
To evaluate the risk of liver‐related events, MACE and death among patients with SLD.
Methods
We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD.
Results
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p < 0.001 for both liver‐related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p < 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver‐related events, MACE and death in MetALD were 1.42 (1.1–1.8), 0.68 (0.63–0.73) and 1.13 (0.98–1.3), respectively. In ALD, they were 3.42 (2.6–4.6), 0.58 (0.49–0.67) and 1.60 (1.3–2.0), respectively, for liver‐related events, MACE and death.
Conclusions
The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease‐specific therapeutic implications.
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD, while the incidence of MACE was highest in MASLD, followed by MetALD and ALD. Therefore, the new consensus nomenclature can be used to stratify the risk of complications and prognosis.</description><identifier>ISSN: 0269-2813</identifier><identifier>ISSN: 1365-2036</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.18015</identifier><identifier>PMID: 38664876</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Death ; Diabetes mellitus ; Dyslipidemia ; Liver diseases ; Mortality ; Nomenclature ; Population studies</subject><ispartof>Alimentary pharmacology & therapeutics, 2024-07, Vol.60 (1), p.61-69</ispartof><rights>2024 John Wiley & Sons Ltd.</rights><rights>Copyright © 2024 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</citedby><cites>FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</cites><orcidid>0000-0003-4634-6616 ; 0000-0002-1481-1029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.18015$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.18015$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38664876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamaki, Nobuharu</creatorcontrib><creatorcontrib>Kimura, Takefumi</creatorcontrib><creatorcontrib>Wakabayashi, Shun‐Ichi</creatorcontrib><creatorcontrib>Umemura, Takeji</creatorcontrib><creatorcontrib>Kurosaki, Masayuki</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Izumi, Namiki</creatorcontrib><title>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown.
Aims
To evaluate the risk of liver‐related events, MACE and death among patients with SLD.
Methods
We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD.
Results
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p < 0.001 for both liver‐related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p < 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver‐related events, MACE and death in MetALD were 1.42 (1.1–1.8), 0.68 (0.63–0.73) and 1.13 (0.98–1.3), respectively. In ALD, they were 3.42 (2.6–4.6), 0.58 (0.49–0.67) and 1.60 (1.3–2.0), respectively, for liver‐related events, MACE and death.
Conclusions
The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease‐specific therapeutic implications.
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD, while the incidence of MACE was highest in MASLD, followed by MetALD and ALD. Therefore, the new consensus nomenclature can be used to stratify the risk of complications and prognosis.</description><subject>Death</subject><subject>Diabetes mellitus</subject><subject>Dyslipidemia</subject><subject>Liver diseases</subject><subject>Mortality</subject><subject>Nomenclature</subject><subject>Population studies</subject><issn>0269-2813</issn><issn>1365-2036</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kc-KFDEQh4Mo7rh68AUk4EXB3k0nk3RyXJb1DwzoYT03NUm1ZEl3xiQ9y9x8hPUVfRKz26MHwVwKUl99FPUj5GXLztr6zmFXzlrNWvmIrFqhZMOZUI_JinFlGq5bcUKe5XzDGFMd40_JidBKrXWnVuTnJk7ffv24K5hGaoOfvIVA41xsHDFTP9FcEEos3tLg95io8xkhI4XJ1bb1DieLNA5Lu6oSBijoKO5xKvkdtZCcj3vIdg6Qjt8P4xBC5S3MVTfGVCD4cnhOngwQMr441lPy9f3V9eXHZvP5w6fLi01jhRSycRy4MQqtFGZQSsuOraW1ej3AlivXOdOBE8AtFxq0kVuo1xBGO-NAttaKU_Jm8e5S_D5jLv3os8UQYMI4516wdWfuj2Qq-vof9CbOaarbVUqpVgvW8Uq9XSibYs4Jh36X_Ajp0Lesv8-przn1DzlV9tXROG9HdH_JP8FU4HwBbn3Aw_9N_cWX60X5G6lmobk</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Tamaki, Nobuharu</creator><creator>Kimura, Takefumi</creator><creator>Wakabayashi, Shun‐Ichi</creator><creator>Umemura, Takeji</creator><creator>Kurosaki, Masayuki</creator><creator>Loomba, Rohit</creator><creator>Izumi, Namiki</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4634-6616</orcidid><orcidid>https://orcid.org/0000-0002-1481-1029</orcidid></search><sort><creationdate>202407</creationdate><title>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</title><author>Tamaki, Nobuharu ; Kimura, Takefumi ; Wakabayashi, Shun‐Ichi ; Umemura, Takeji ; Kurosaki, Masayuki ; Loomba, Rohit ; Izumi, Namiki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Death</topic><topic>Diabetes mellitus</topic><topic>Dyslipidemia</topic><topic>Liver diseases</topic><topic>Mortality</topic><topic>Nomenclature</topic><topic>Population studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamaki, Nobuharu</creatorcontrib><creatorcontrib>Kimura, Takefumi</creatorcontrib><creatorcontrib>Wakabayashi, Shun‐Ichi</creatorcontrib><creatorcontrib>Umemura, Takeji</creatorcontrib><creatorcontrib>Kurosaki, Masayuki</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Izumi, Namiki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamaki, Nobuharu</au><au>Kimura, Takefumi</au><au>Wakabayashi, Shun‐Ichi</au><au>Umemura, Takeji</au><au>Kurosaki, Masayuki</au><au>Loomba, Rohit</au><au>Izumi, Namiki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2024-07</date><risdate>2024</risdate><volume>60</volume><issue>1</issue><spage>61</spage><epage>69</epage><pages>61-69</pages><issn>0269-2813</issn><issn>1365-2036</issn><eissn>1365-2036</eissn><abstract>Summary
Background
A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown.
Aims
To evaluate the risk of liver‐related events, MACE and death among patients with SLD.
Methods
We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD.
Results
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p < 0.001 for both liver‐related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p < 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver‐related events, MACE and death in MetALD were 1.42 (1.1–1.8), 0.68 (0.63–0.73) and 1.13 (0.98–1.3), respectively. In ALD, they were 3.42 (2.6–4.6), 0.58 (0.49–0.67) and 1.60 (1.3–2.0), respectively, for liver‐related events, MACE and death.
Conclusions
The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease‐specific therapeutic implications.
The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD, while the incidence of MACE was highest in MASLD, followed by MetALD and ALD. Therefore, the new consensus nomenclature can be used to stratify the risk of complications and prognosis.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38664876</pmid><doi>10.1111/apt.18015</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4634-6616</orcidid><orcidid>https://orcid.org/0000-0002-1481-1029</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 2024-07, Vol.60 (1), p.61-69 |
issn | 0269-2813 1365-2036 1365-2036 |
language | eng |
recordid | cdi_proquest_miscellaneous_3047948769 |
source | EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
subjects | Death Diabetes mellitus Dyslipidemia Liver diseases Mortality Nomenclature Population studies |
title | Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A41%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20clinical%20outcomes%20in%20steatotic%20liver%20disease%20and%20incidence%20of%20liver%E2%80%90related%20events,%20cardiovascular%20events%20and%20all%E2%80%90cause%20mortality&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Tamaki,%20Nobuharu&rft.date=2024-07&rft.volume=60&rft.issue=1&rft.spage=61&rft.epage=69&rft.pages=61-69&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.18015&rft_dat=%3Cproquest_cross%3E3066183072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3066183072&rft_id=info:pmid/38664876&rfr_iscdi=true |